Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.34 |
| ▸ | CASP1 | P29466 | 9/20 | 0.34 |
| ▸ | CASP3 | P42574 | 9/20 | 0.34 |
| ▸ | CASP7 | P55210 | 7/20 | 0.34 |
| ▸ | CASP6 | P55212 | 6/20 | 0.34 |
| ▸ | CASP8 | Q14790 | 5/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950252 | 0.95 | CASP1 (0.35) | NAAACASP1CASP3CASP7CASP6 | |
| SCHEMBL948261 | 0.93 | CASP3 (0.35) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL949258 | 0.88 | CASP3 (0.38) | NAAACASP1CASP3CASP7CASP6 | |
| SCHEMBL949088 | 0.83 | CASP1 (0.35) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL950251 | 0.83 | CASP3 (0.39) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL949530 | 0.82 | CASP3 (0.38) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL949112 | 0.81 | CASP1 (0.35) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL948259 | 0.80 | CASP3 (0.40) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL948808 | 0.79 | CASP3 (0.38) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL4455598 | 0.78 | PDE2A (0.34) | CASP1CASP3CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2123665-A2 | Inhibitors of interleukin-1Beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1394175-A1 | Inhibitors of interleukin-1beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | NAAA 1000/4885CASP1 5/4885CASP3 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.